Press releaseGlobe Newswire
Damora Therapeutics
DMRA · NASDAQ
$20.67+$1.40 (+7.27%)TodayMarket closed ·
Prev close $19.27
Latest news
- Press releaseGlobe Newswire
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
- News
Damora Therapeutics Says On Track For First Regulatory Submission For DMR-001 In Mid-2026
- Press releaseGlobe Newswire
Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.